Page 77 - Flipbook January Board
P. 77
Robert Packer Hospital
Clinical Quality Committee Meeting
DATE: Tuesday, December 11, 2018
TIME: Noon
Present: Joseph Ronsivalle, DO (Chair), Douglas Trostle, MD, Willow Bronson-Golay, Kelly Coldiron, Barb Pennypacker, Jill Stenson, Nicole
Teeter, Vania Brown-Small, Barb Gordon, Michael Gum, Barbara Hayes, Renee Jankowski, Kim Joedicke, Andrew Klee, Deb Luchaco, Melissa,
Susan Sinay, Kim Worden, Sergio Zullich, Janet Cunningham, Kristen Nash, DO.
Meeting Started: 12:02 PM Meeting Adjourned: 1:02 PM
TOPIC DISCUSSION/CONCLUSION RECOMMENDATIONS/
ACTION/FOLLOW UP
/RESPONSIBLE PARTY
I. Old Business Minutes from December 11, 2018 were reviewed. Dr. Ronsivalle motioned to accept Minutes Approved
minutes as presented, seconded by Sergio Zullich and Janet Cunningham. There was no
dissent.
II. Pharmacy & Kim Joedicke provided report from Pharmacy and Therapeutics Committee. Motion to approve formulary
Therapeutics – Copy of • Reported Adverse Drug Reactions (ADRs) and Medication Errors for October changes and policy revisions
presentation attached to 2018 included 31 ADRs with 2 determined to be preventable and 21 medication made by Dr. Ronsivalle,
official minutes errors. seconded by Jill Stenson and
• Infusion Center formulary changes for approval: Dr. Trostle, there was no
o Add Infliximab-Abda (Renflexis) as second biosimilar to Remicade (first dissent. Motion carried.
biosimilar is Inflectra). Inflectra is the most cost effective and should be
first choice for NEW starts unless insurance dictates otherwise.
o Conversion of IVIG from Gammunex-C to Privigen. Privigen is currently
the most cost effective IVIG product. All new starts should use Privigen.
Current patients will transition to Privigen at the approval of their provider
with a new order. Potential annual cost savings of $130,000 systemwide.
• Policy changes for approval:
o Controlled Medications RPH-A-744-2202 revised, nursing will no longer
inventory controlled substances in Automated Dispensing Machines.
o Medication Storage and Security RPH-A-744-2200 revised to include
dispensing process for first doses on cartless units and the stocking
process for IV fluids by Supply and Distribution personnel.
o Medication Dispensing and Distribution RPH-A-744-4100 revised to
include bedside medication boxes as a medication storage location.
o Omnicell Anesthesia System RPH-A-744-2208 revised due to the
transition from Aesynt Anesthesia Carts to Omnicell Anesthesia Carts.
• P&T Committee to review Andexanet Alfa (Andexxa) which reverses bleeding
related to the use of Rivaroxaban (Xarelto) and Apixaban (Eliquis) ONLY.
1